Medical imaging firm Hologic is acquiring German biopsy site marker manufacturer Somatex for $64 million, the two companies announced Monday.
Marlborough, Massachusetts-based Hologic said the deal will allow it to offer a full suite of breast health services and expand sales in Europe.
“We’ve had a strong partnership with Somatex for several years, which along with our shared focus on innovation, will allow us to quickly integrate and begin building a pipeline that will drive profitable growth and recurring revenue for our breast health business globally,” Jennifer Meade, Hologic’s division president in breast and skeletal health solutions, said in a statement.
Around since 1992, Somatex has about 50 employees, specializing in the development and manufacturing of devices in tumor diagnostics, biopsies and interventional specialties. That includes its Tumark line of tissue markers, which Hologic distributed in the U.S. prior to the deal.
E-Med Solutions, a Berlin-based group of investors, previously owned Somatex. Following the acquisition, Hologic said it generated some $13 million worth of revenue in calendar 2020, according to the announcement.